Different SNPs in Fasciola hepatica P-glycoprotein from diverse Latin American populations are not associated with Triclabendazole resistance.

[1]  Santiago Fontenla,et al.  Pleiotropic alterations in gene expression in Latin American Fasciola hepatica isolates with different susceptibility to drugs , 2018, Parasites & Vectors.

[2]  Juan C. Sánchez-DelBarrio,et al.  DnaSP 6: DNA Sequence Polymorphism Analysis of Large Data Sets. , 2017, Molecular biology and evolution.

[3]  K. Mehmood,et al.  A review on epidemiology, global prevalence and economical losses of fasciolosis in ruminants. , 2017, Microbial pathogenesis.

[4]  S. Paterson,et al.  Fasciola hepatica demonstrates high levels of genetic diversity, a lack of population structure and high gene flow: possible implications for drug resistance , 2017, International journal for parasitology.

[5]  Samantha N. McNulty,et al.  Genomes of Fasciola hepatica from the Americas Reveal Colonization with Neorickettsia Endobacteria Related to the Agents of Potomac Horse and Human Sennetsu Fevers , 2017, PLoS genetics.

[6]  J. Tort,et al.  Fasciolosis in South America: epidemiology and control challenges , 2016, Journal of Helminthology.

[7]  T. Beddoe,et al.  Current Threat of Triclabendazole Resistance in Fasciola hepatica. , 2016, Trends in parasitology.

[8]  T. Itagaki,et al.  Molecular characterization and phylogenetic analysis of Fasciola hepatica from Peru. , 2016, Parasitology international.

[9]  M. Nyindo,et al.  Fascioliasis: An Ongoing Zoonotic Trematode Infection , 2015, BioMed research international.

[10]  J. Dalton,et al.  The Fasciola hepatica genome: gene duplication and polymorphism reveals adaptation to the host environment and the capacity for rapid evolution , 2015, Genome Biology.

[11]  T. Spithill,et al.  The T687G SNP in a P-glycoprotein gene of Fasciola hepatica is not associated with resistance to triclabendazole in two resistant Australian populations. , 2014, Molecular and biochemical parasitology.

[12]  P. Ortiz,et al.  Resistance of Fasciola hepatica against Triclabendazole in cattle in Cajamarca (Peru): a clinical trial and an in vivo efficacy test in sheep. , 2013, Veterinary parasitology.

[13]  I. Fairweather,et al.  Increased susceptibility of a triclabendazole (TCBZ)-resistant isolate of Fasciola hepatica to TCBZ following co-incubation in vitro with the P-glycoprotein inhibitor, R(+)-verapamil , 2013, Parasitology.

[14]  D. Williams,et al.  Identification of putative markers of triclabendazole resistance by a genome-wide analysis of genetically recombinant Fasciola hepatica , 2013, Parasitology.

[15]  C. Lanusse,et al.  Identification of a field isolate of Fasciola hepatica resistant to albendazole and susceptible to triclabendazole. , 2013, Veterinary parasitology.

[16]  C. Lanusse,et al.  Testing albendazole resistance in Fasciola hepatica: validation of an egg hatch test with isolates from South America and the United Kingdom , 2013, Journal of Helminthology.

[17]  I. Fairweather,et al.  An amino acid substitution in Fasciola hepatica P-glycoprotein from triclabendazole-resistant and triclabendazole-susceptible populations. , 2012, Molecular and biochemical parasitology.

[18]  V. Lovera,et al.  Resistance of Fasciola hepatica against triclabendazole in cattle in Patagonia (Argentina). , 2011, Veterinary parasitology.

[19]  G. Virkel,et al.  Understanding triclabendazole resistance. , 2007, Experimental and molecular pathology.

[20]  G. Virkel,et al.  Altered drug influx/efflux and enhanced metabolic activity in triclabendazole-resistant liver flukes , 2005, Parasitology.